StockData
Ocugen, Inc. logo

Ocugen, Inc. (OCGN) shareholders

OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$0.77−0.05 (-6.62%)

Close on Nov 16, 2026Market cap $262.13MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
42.8%
145M of 339M shares
Institutional holders
147
43 new, 31 sold out
Net institutional buying
34M
In Q2 2026
Insider trades, 12 months
1 buys · 4 sales
Net sold $1.06M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.26,952,4928.00%13G (passive)Jun 30, 2026
State Street Corporation21,469,3076.30%13G (passive)Jun 30, 2026
Janus Henderson Group PLC20,000,0006.00%13G (passive)Nov 28, 2025
Millennium Management LLC
Joint filing with Millennium Group Management LLC (5.20%), Israel A. Englander (5.20%)
17,074,5845.20%13G (passive)Apr 9, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of OCGNValueChange% of portfolio
BlackRock, Inc.27,002,9337.96%$41.31M+19,697,9540.00%
State Street Corp21,469,3076.33%$32.85M+11,799,1160.00%
Vanguard Capital Management LLC14,372,5984.24%$21.99M+568,4870.00%
Millennium Management LLC13,943,2524.11%$21.33M+216,0600.01%
Geode Capital Management, LLC8,871,0132.62%$13.58M+4,643,9090.00%
Rtw Investments, LP6,666,6661.97%$10.20M–0.09%
UBS Group AG5,177,5081.53%$7.92M−2,102,8120.00%
Ikarian Capital, LLC3,962,9721.17%$6.06M–0.65%
Gmt Capital Corp3,505,3981.03%$5.36M–0.28%
Marshall Wace, Llp3,410,2571.01%$5.22M−4,642,0930.00%
Vanguard Portfolio Management LLC3,329,4460.98%$5.09M+2,393,6470.00%
Hennion & Walsh Asset Management, Inc.2,830,3970.83%$4.33M+1,553,6720.12%
Northern Trust Corp2,747,5620.81%$4.20M+2,033,8260.00%
Vanguard Fiduciary Trust Co2,367,1440.70%$3.62M+366,0410.00%
Two Sigma Investments, LP2,230,1790.66%$3.41M−21,1030.00%
Qube Research & Technologies Ltd2,203,4070.65%$3.37M−1,569,6590.00%
Bank Of America Corp /De/1,990,6360.59%$3.05M+816,4560.00%
Hrt Financial LP1,768,2970.52%$2.71M+1,391,7030.00%
Boothbay Fund Management, LLC1,097,7420.32%$1.68M–0.02%
Charles Schwab Investment Management Inc1,042,5370.31%$1.60M+830,4430.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026147145M42.8%43 / 4627 / 3154M20M
Q1 2026137111M32.7%47 / 4321 / 1673M7M
Q4 202510962M18.2%30 / 3319 / 1423M7M
Q3 20259746M13.5%18 / 2135 / 244M11M
Q2 202510452M15.4%33 / 2825 / 3914M39M
Q1 202511077M22.6%18 / 3829 / 2110M5M
Q4 202411472M21.1%26 / 3129 / 258M16M
Q3 202411580M23.5%32 / 3422 / 1732M2M
Q2 202410167M19.9%44 / 2412 / 2342M9M
Q1 20248135M10.2%27 / 247 / 1411M3M
Q4 20236827M7.9%11 / 1619 / 211M8M
Q3 20237833M9.7%5 / 2022 / 231M17M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

73 funds held OCGN in Q2 2026, 87% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of OCGNValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF13,986,4184.12%$21.40M0.20%Jun 30, 2026
Vanguard Total Stock Market Index Fund10,177,0943.00%$15.57M0.00%Jun 30, 2026
iShares Russell 2000 ETF8,719,9642.57%$13.34M0.02%Jun 30, 2026
Vanguard Extended Market Index Fund3,882,8931.15%$5.94M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund3,707,3541.09%$4.56M0.01%Jul 31, 2026
iShares Russell 2000 Growth ETF2,209,8740.65%$3.38M0.02%Jun 30, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF1,818,2150.54%$2.78M0.10%Jun 30, 2026
Fidelity Extended Market Index Fund1,704,6940.50%$2.35M0.01%May 31, 2026
iShares Micro-Cap ETF1,147,8930.34%$1.76M0.12%Jun 30, 2026
iShares Russell 2000 Value ETF996,7120.29%$1.52M0.01%Jun 30, 2026
Vanguard Health Care Index Fund931,6710.27%$1.29M0.01%May 31, 2026
Schwab Small-Cap Index Fund830,7990.24%$1.02M0.01%Jul 31, 2026
iShares Genomics Immunology and Healthcare ETF723,7830.21%$890.25K0.47%Jul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF661,5970.20%$1.01M0.00%Jun 30, 2026
Master Small Cap Index Series638,8290.19%$977.41K0.02%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Shankar MusunuriChief Executive Officer, Director5,049,2411.49%Oct 13, 2026
Treerita Essalima Johnson-GreeneChief Financial Officer521,3500.15%Jun 17, 2026
Ramesh RamachandranChief Accounting Officer209,1000.06%Jan 6, 2026
Arun UpadhyaySee Remarks306,1970.09%Jan 6, 2025
Huma QamarChief Medical Officer1,6430.00%Jan 6, 2025
Junge ZhangDirector2,369,5690.70%Jun 15, 2026
Kirsten CastilloDirector75,0000.02%Jun 15, 2026
Uday KompellaDirector705,0900.21%Jun 15, 2026
Satishchandran ChandrasekharDirector––Jun 15, 2026
Blaise ColemanDirector––Jun 15, 2026
Prabhavathi FernandesDirector10,0000.00%Dec 2, 2024

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Shankar Musunuri
Chief Executive Officer, Director
Oct 9, 2026Sale(10b5-1 plan)−57,264$0.95$54.40K1,030,771
Shankar Musunuri
Chief Executive Officer, Director
Oct 9, 2026Sale(10b5-1 plan)−468,727$0.95$445.29K4,018,470
Shankar Musunuri
Chief Executive Officer, Director
Sep 9, 2026Sale(10b5-1 plan)−57,264$1.12$64.14K1,088,035
Shankar Musunuri
Chief Executive Officer, Director
Sep 9, 2026Sale(10b5-1 plan)−468,727$1.12$524.97K4,487,197
Treerita Essalima Johnson-Greene
Chief Financial Officer
Jun 15, 2026Buy+21,000$1.23$25.83K521,000
Junge Zhang
Director
Apr 1, 2026Option exercise+112,205$0.46$51.61K1,292,387
Junge Zhang
Director
Apr 1, 2026Option exercise+15,000$0.51$7.65K1,180,182
Junge Zhang
Director
Apr 1, 2026Option exercise+66,929$1.42$95.04K1,359,316
Shankar Musunuri
Chief Executive Officer, Director
Jan 2, 2026Award+3,123,201––4,955,924
Ramesh Ramachandran
Chief Accounting Officer
Jan 2, 2026Award+207,300––209,100
Arun Upadhyay
See Remarks
Jan 3, 2025Tax withholding−41,633$0.89$37.05K306,197
Shankar Musunuri
Chief Executive Officer, Director
Jan 3, 2025Tax withholding−177,146$0.89$157.66K1,832,723
Prabhavathi Fernandes
Director
Nov 26, 2024Buy+10,000$0.91$9.10K10,000
Kirsten Castillo
Director
Nov 22, 2024Buy+25,000$0.91$22.75K75,000
Arun Upadhyay
See Remarks
Sep 16, 2024Tax withholding−842$1.17$985347,830
Arun Upadhyay
See Remarks
Jun 17, 2024Tax withholding−917$1.42$1.30K348,672
Shankar Musunuri
Chief Executive Officer, Director
Jan 3, 2024Tax withholding−180,204$0.65$117.13K2,009,869
Arun Upadhyay
See Remarks
Jan 3, 2024Tax withholding−41,633$0.65$27.06K349,589
Arun Upadhyay
See Remarks
Sep 16, 2023Tax withholding−842$0.41$345391,222
Arun Upadhyay
Chief Scientific Officer
Jun 16, 2023Tax withholding−917$0.51$468392,064
Junge Zhang
Director
Jun 14, 2023Buy+200,278$0.50$100.14K1,077,182
Shankar Musunuri
Chief Executive Officer, Director
Feb 16, 2023Sale(10b5-1 plan)−100,000$1.08$108.00K2,190,073
Shankar Musunuri
Chief Executive Officer, Director
Feb 16, 2023Option exercise+100,000$0.33$33.00K2,290,073
Shankar Musunuri
Chief Executive Officer, Director
Jan 17, 2023Option exercise+100,000$0.51$51.00K2,327,950
Shankar Musunuri
Chief Executive Officer, Director
Jan 17, 2023Sale(10b5-1 plan)−100,000$1.28$128.00K2,227,950
Jessica Crespo
CAO/SVP, Finance
Jan 3, 2023Tax withholding−1,913$1.25$2.39K161,478
Arun Upadhyay
Chief Scientific Officer
Jan 3, 2023Tax withholding−7,102$1.25$8.88K392,981
Shankar Musunuri
Chief Executive Officer, Director
Jan 3, 2023Tax withholding−37,877$1.25$47.35K2,190,073
Jessica Crespo
CAO/SVP, Finance
Jan 3, 2023Award+122,951––163,391
Arun Upadhyay
Chief Scientific Officer
Jan 3, 2023Award+315,924––400,083
Shankar Musunuri
Chief Executive Officer, Director
Jan 3, 2023Award+1,475,410––2,227,950
Shankar Musunuri
Chief Executive Officer, Director
Dec 16, 2022Option exercise+95,809$0.51$48.86K848,349
Shankar Musunuri
Chief Executive Officer, Director
Dec 16, 2022Sale(10b5-1 plan)−95,809$1.43$137.01K752,540
Shankar Musunuri
Chief Executive Officer, Director
Oct 14, 2022Sale(10b5-1 plan)−100,000$1.66$166.00K752,540
Shankar Musunuri
Chief Executive Officer, Director
Oct 14, 2022Option exercise+100,000$0.51$51.00K852,540
Ramesh Kumar
Director
Oct 6, 2022Sale(10b5-1 plan)−4,500$1.83$8.24K0
Ramesh Kumar
Director
Oct 6, 2022Option exercise+4,500$0.51$2.30K4,500
Kirsten Castillo
Director
Aug 11, 2022Option exercise+42,000$0.28$11.76K92,000
Kirsten Castillo
Director
Aug 11, 2022Sale−42,000$2.91$122.22K50,000
Ramesh Kumar
Director
Jul 18, 2022Option exercise+7,500$0.51$3.83K7,500
Ramesh Kumar
Director
Jul 18, 2022Sale(10b5-1 plan)−7,500$2.57$19.28K0
Shankar Musunuri
Chief Executive Officer, Director
Jul 14, 2022Sale(10b5-1 plan)−150,000$2.72$408.00K752,540
Shankar Musunuri
Chief Executive Officer, Director
Jul 14, 2022Option exercise+150,000$0.33$49.50K902,540
Shankar Musunuri
Chief Executive Officer, Director
May 13, 2022Sale(10b5-1 plan)−125,000$1.92$240.00K752,540
Shankar Musunuri
Chief Executive Officer, Director
May 13, 2022Option exercise+125,000$0.33$41.25K877,540
Ramesh Kumar
Director
Apr 18, 2022Sale(10b5-1 plan)−7,500$2.83$21.23K0
Ramesh Kumar
Director
Apr 18, 2022Option exercise+7,500$0.51$3.83K7,500
Jessica Crespo
CAO/SVP, Finance
Mar 18, 2022Award+22,940––40,440
Shankar Musunuri
Chief Executive Officer, Director
Mar 16, 2022Option exercise+81,823$0.33$27.00K834,363
Shankar Musunuri
Chief Executive Officer, Director
Mar 16, 2022Sale(10b5-1 plan)−81,823$2.65$216.83K752,540
Junge Zhang
Director
Mar 3, 2022Option exercise+39,000$0.51$19.89K39,000
Junge Zhang
Director
Mar 3, 2022Option exercise+49,000$1.83$89.67K88,000
Shankar Musunuri
Chief Executive Officer, Director
Feb 14, 2022Sale(10b5-1 plan)−90,000$3.74$336.60K752,540
Shankar Musunuri
Chief Executive Officer, Director
Feb 14, 2022Option exercise+90,000$0.33$29.70K842,540
Ramesh Kumar
Director
Jan 18, 2022Option exercise+7,500$0.51$3.83K7,500
Ramesh Kumar
Director
Jan 18, 2022Sale(10b5-1 plan)−7,500$4.07$30.53K0
Sanjay Subramanian
Chief Financial Officer
Jan 3, 2022Award+125,534––161,125
Shankar Musunuri
Chief Executive Officer, Director
Jan 3, 2022Award+346,540––752,540
Manish Potti
Director
Dec 16, 2021Option exercise+31,500$1.83$57.65K45,000
Manish Potti
Director
Dec 16, 2021Option exercise+13,500$0.51$6.89K13,500

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
32.54%
108M shares short
Days to cover
16.4
At 7M shares a day
Change since last report
+0.5%
From 107M shares
Short volume, 20 days
64.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ocugen's stock actually held short. Settlement fails (shares not delivered on time) peaked at 603,805 shares on Oct 13, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Shankar Musunuri
Officer
Oct 9, 2026525,991$497.96KOct 9, 2026Equity Compensation
Shankar Musunuri
Officer
Sep 9, 2026525,991$589.74KSep 9, 2026Equity Compensation
Marna C. Whittington
Director
Jul 9, 2025112,205$122.89KJul 9, 2025Stock Option Exercise
Prabhavathi Fernandes
Director
Jun 11, 2025146,705$171.03KJun 11, 2025Stock Option Exercise
Ramesh Kumar
Director
Aug 16, 2024116,705$145.90KAug 16, 2024Stock Option Exercise

Congress trades

2 trades in Ocugen reported by 1 member of the House

MemberTypeTradedAmountFiled
Christopher L. Jacobs
NY27
SoldNov 8, 2022$1K–15KDec 12, 2022
Christopher L. Jacobs
NY27
BoughtJun 16, 2022$15K–50KJul 28, 2022

See a number that looks wrong?